Therapeutic Silencing of MicroRNA-33 Inhibits the Progression of Atherosclerosis in <i>Ldlr</i> ^−/− Mice—Brief Report

Abstract

Long-term anti-miR-33 therapy significantly reduces the progression of atherosclerosis and improves HDL functionality. The antiatherogenic effect is independent of plasma HDL-cholesterol levels.